Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Invested Capital (2020 - 2024)

Immuneering (IMRX) has 5 years of Invested Capital data on record, last reported at $57.7 million in Q3 2024.

  • For Q3 2024, Invested Capital fell 44.51% year-over-year to $57.7 million; the TTM value through Sep 2024 reached $57.7 million, down 44.51%, while the annual FY2023 figure was $90.6 million, 17.55% down from the prior year.
  • Invested Capital reached $57.7 million in Q3 2024 per IMRX's latest filing, down from $66.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $158.3 million in Q3 2021 and bottomed at -$35.2 million in Q2 2021.
  • Average Invested Capital over 5 years is $73.2 million, with a median of $94.2 million recorded in 2023.
  • The widest YoY moves for Invested Capital: up 1038.75% in 2021, down 175.46% in 2021.
  • A 5-year view of Invested Capital shows it stood at -$22.5 million in 2020, then surged by 793.82% to $156.0 million in 2021, then dropped by 29.57% to $109.9 million in 2022, then decreased by 17.55% to $90.6 million in 2023, then plummeted by 36.27% to $57.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $57.7 million in Q3 2024, $66.3 million in Q2 2024, and $78.7 million in Q1 2024.